Characteristics and Distribution of Scholarship Donations From Pharmaceutical Companies to Japanese Healthcare Institutions in 2017: A Cross-sectional Analysis

Document Type : Original Article

Authors

1 Tohoku University School of Medicine, Sendai, Japan

2 Medical Governance Research Institute, Tokyo, Japan

3 Department of Internal Medicine, Soma Central Hospital, Soma, Japan

4 Department of Internal Medicine, Navitas Clinic Kawasaki, Kawasaki, Japan

5 Department of Social and Policy Sciences, University of Bath, Bath, UK

6 Department of Breast and Thyroid Surgery, Jyoban Hospital of Tokiwa Foundation, Iwaki, Japan

Abstract

Background 
Financial relationships between healthcare institutions and pharmaceutical companies can lead to conflicts of interest (COIs), potentially compromising patients’ care. In Japan, scholarship donations, unique type of payments made to healthcare institutions and their subunits by pharmaceutical industries without restricting their use including non-educational or research purpose, may often have implicit promotional purposes. However, detailed information about these payments remains scarce.

Methods 
This study employed a cross-sectional design to analyse the extent and distribution of all scholarship donations made by all 73 pharmaceutical companies belonging to the Japan Pharmaceutical Manufacturers Association (JPMA) to healthcare institutions in 2017. Data were obtained from publicly available sources from the companies, and the total
number of payments, their distributions across various institutions and specialties were analysed.

Results 
A total of 27 007 payment contracts amounting to $178 703 721 in scholarship donations were made to 4839 specific departments and laboratories at 251 different institutions by 67 pharmaceutical companies. National universities received 50.8% of total payments. All universities setting medical school in Japan received one or more payments. Domestic pharmaceutical companies contributed to $137 797 302 (77.1%) in total. Clinical medicine departments received 89.6% ($160 113 147) with 6.2% ($11 011 946) and 2.0% ($3 600 456) allocated to basic medicine and social medicine specialties, respectively.

Conclusion 
This study provided a comprehensive overview of scholarship donations from pharmaceutical companies to healthcare institutions in Japan, revealing significant financial support primarily directed to national universities and clinical medicine departments. Japanese policy-makers should consider implementing regulations that promote transparency and mitigate potential COIs arising from scholarship donations, which may be useful in other countries with similar schemes.

Keywords

References

  1. Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009-2018. JAMA. 2020;323(9):844-853. doi:1001/jama.2020.1166
  2. Rubin EH, Gilliland DG. Drug development and clinical trials--the path to an approved cancer drug. Nat Rev Clin Oncol. 2012;9(4):215-222. doi:1038/nrclinonc.2012.22
  3. Institute of Medicine. Conflict of Interest in Medical Research, Education, and Practice. Washington, DC: National Academies Press; 2009.
  4. Tijdink JK, Smulders YM, Bouter LM, Vinkers CH. The effects of industry funding and positive outcomes in the interpretation of clinical trial results: a randomized trial among Dutch psychiatrists. BMC Med Ethics. 2019;20(1):64. doi:1186/s12910-019-0405-7
  5. DeJong C, Aguilar T, Tseng CW, Lin GA, Boscardin WJ, Dudley RA. Pharmaceutical industry-sponsored meals and physician prescribing patterns for Medicare beneficiaries. JAMA Intern Med. 2016;176(8):1114-1122. doi:1001/jamainternmed.2016.2765
  6. Fickweiler F, Fickweiler W, Urbach E. Interactions between physicians and the pharmaceutical industry generally and sales representatives specifically and their association with physicians' attitudes and prescribing habits: a systematic review. BMJ Open. 2017;7(9):e016408. doi:1136/bmjopen-2017-016408
  7. Mitchell AP, Trivedi NU, Gennarelli RL, et al. Are financial payments from the pharmaceutical industry associated with physician prescribing? A systematic review. Ann Intern Med. 2021;174(3):353-361. doi:7326/m20-5665
  8. Johnson L, Stricker RB. Attorney General forces Infectious Diseases Society of America to redo Lyme guidelines due to flawed development process. J Med Ethics. 2009;35(5):283-288. doi:1136/jme.2008.026526
  9. Steinbrook R. Guidance for guidelines. N Engl J Med. 2007;356(4):331-333. doi:1056/NEJMp068282
  10. Ozaki A, Murayama A, Harada K, et al. How do institutional conflicts of interest between pharmaceutical companies and the healthcare sector become corrupt? A case study of scholarship donations between department of clinical anesthesiology, Mie University, and ono pharmaceutical in Japan. Front Public Health. 2021;9:762637. doi:3389/fpubh.2021.762637
  11. Sawano T, Ozaki A, Saito H, Shimada Y, Tanimoto T. Payments from pharmaceutical companies to authors involved in the valsartan scandal in Japan. JAMA Netw Open. 2019;2(5):e193817. doi:1001/jamanetworkopen.2019.3817
  12. Muramatsu T, Matsushita K, Yamashita K, et al. Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: NAGOYA HEART Study. Hypertension. 2012;59(3):580-586. doi:1161/hypertensionaha.111.184226
  13. Uzu T, Sawaguchi M, Maegawa H, Kashiwagi A. Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART). Diabetes Care. 2007;30(6):1581-1583. doi:2337/dc06-2493
  14. Sawada T, Yamada H, Dahlöf B, Matsubara H. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur Heart J. 2009;30(20):2461-2469. doi:1093/eurheartj/ehp363
  15. Mochizuki S, Dahlöf B, Shimizu M, et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet. 2007;369(9571):1431-1439. doi:1016/s0140-6736(07)60669-2
  16. Narumi H, Takano H, Shindo S, et al. Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial. Hypertens Res. 2011;34(1):62-69. doi:1038/hr.2010.186
  17. Murata N, Ozaki A, Murayama A, Sawano T, Tanimoto T. The Diovan scandal in Japan; don't let bygones be bygones. J Hum Hypertens. 2022;36(5):500-501. doi:1038/s41371-022-00680-2
  18. Ozaki A, Saito H, Senoo Y, et al. Overview and transparency of non-research payments to healthcare organizations and healthcare professionals from pharmaceutical companies in Japan: analysis of payment data in 2016. Health Policy. 2020;124(7):727-735. doi:1016/j.healthpol.2020.03.011
  19. Murayama A, Hoshi M, Saito H, et al. Nature and trends in personal payments made to the respiratory physicians by pharmaceutical companies in Japan between 2016 and 2019. Respiration. 2022;101(12):1088-1098. doi:1159/000526576
  20. Mamada H, Murayama A, Ozaki A, et al. Observational study of financial and non-financial conflicts of interest among the Japanese government advisory board members concerning coronavirus disease 2019. Medicine (Baltimore). 2023;102(4):e32776. doi:1097/md.0000000000032776
  21. Murayama A, Mamada H, Shigeta H, et al. Financial relationships between pharmaceutical companies and rheumatologists in Japan between 2016 and 2019. J Clin Rheumatol. 2023;29(3):118-125. doi:1097/rhu.0000000000001922
  22. Murayama A, Saito H, Tanimoto T, Ozaki A. Financial conflicts of interest between pharmaceutical companies and executive board members of internal medicine subspecialty societies in Japan between 2016 and 2020. J Eval Clin Pract. 2023. doi:1111/jep.13877
  23. Hashimoto T, Murayama A, Mamada H, Saito H, Tanimoto T, Ozaki A. Evaluation of financial conflicts of interest and drug statements in the coronavirus disease 2019 clinical practice guideline in Japan. Clin Microbiol Infect. 2022;28(3):460-462. doi:1016/j.cmi.2021.11.019
  24. Murayama A, Ozaki A, Saito H, Sawano T, Sah R, Tanimoto T. Coronavirus disease 2019 experts appearing on Japanese television: their characteristics and financial conflicts of interest with pharmaceutical companies. Clin Microbiol Infect. 2020;27(5):805-807. doi:1016/j.cmi.2020.12.002
  25. Kida F, Murayama A, Saito H, Ozaki A, Shimada Y, Tanimoto T. Pharmaceutical company payments to authors of the Japanese clinical practice guidelines for hepatitis C treatment. Liver Int. 2021;41(3):464-469. doi:1111/liv.14761
  26. Murayama A, Yamada K, Yoshida M, et al. Evaluation of conflicts of interest among participants of the Japanese nephrology clinical practice guideline. Clin J Am Soc Nephrol. 2022;17(6):819-826. doi:2215/cjn.14661121
  27. Kusumi E, Murayama A, Kamamoto S, et al. Pharmaceutical payments to Japanese certified hematologists: a retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019. Blood Cancer J. 2022;12(4):54. doi:1038/s41408-022-00656-y
  28. Murayama A, Kamamoto S, Murata N, et al. Evaluation of financial conflicts of interest and quality of evidence in Japanese gastroenterology clinical practice guidelines. J Gastroenterol Hepatol. 2023;38(4):565-573. doi:1111/jgh.16089
  29. Anderson TS, Gellad WF, Good CB. Characteristics of biomedical industry payments to teaching hospitals. Health Aff (Millwood). 2020;39(9):1583-1591. doi:1377/hlthaff.2020.00385
  30. Anderson TS, Krieger MS, Marshall BDL, Cerdá M, Hadland S. Financial payments to teaching hospitals by companies marketing opioids. J Gen Intern Med. 2020;35(10):3108-3110. doi:1007/s11606-019-05596-1
  31. Ozieranski P, Csanadi M, Rickard E, Tchilingirian J, Mulinari S. Analysis of pharmaceutical industry payments to UK health care organizations in 2015. JAMA Netw Open. 2019;2(6):e196253. doi:1001/jamanetworkopen.2019.6253
  32. Saghy E, Mulinari S, Ozieranski P. Drug company payments to general practices in England: cross-sectional and social network analysis. PLoS One. 2021;16(12):e0261077. doi:1371/journal.pone.0261077
  33. Moberly T. CCGs fail to declare pharma funding. BMJ. 2018;360:j5911. doi:1136/bmj.j5911

Files

History

  • Receive Date: 16 August 2022
  • Revise Date: 17 July 2023
  • Accept Date: 31 July 2023
  • First Publish Date: 05 August 2023

Share

How to cite

Statistics